NEW YORK and LONDON, May 16, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq:AKTX), a late-stage biotechnology company focused on advanced therapies for autoimmune and inflammatory diseases, today announced financial results for the full year ended December 31, 2021, as well as recent pipeline progress.
Read more at globenewswire.comAkari Therapeutics Reports Full Year 2021 Financial Results and Highlights Clinical Progress
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here